# Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

> **NCT07437170** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Children's Hospital of Zhejiang University School of Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Pediatric Acute Myeloid Leukemia
- NUP98 Fusion-positive Acute Myeloid Leukemia

## Interventions

- **DRUG:** Selinexor
- **DRUG:** ZJCH-AML Standardized Chemotherapy

## Key facts

- **NCT ID:** NCT07437170
- **Lead sponsor:** The Children's Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07437170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07437170, "Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07437170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*